ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.394,93
-0,11%
S&P 500
6.101,24
-0,29%
Dow Jones
44.424,25
-0,32%
Euro vs US Dollar
1,04598
-0,41%
Bitcoin
99.783,87
-2,80%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Compugen Ltd (CGEN)

  7. Compugen Ltd (CGEN) News

CGEN

Compugen (CGEN)

Compugen Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CGEN
DatumZeitQuelleÜberschriftSymbolFirma
08/01/202513h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
08/01/202513h00PR Newswire (US)Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid TumorsNASDAQ:CGENCompugen Ltd
27/11/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
27/11/202413h00PR Newswire (US)Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG AntibodiesNASDAQ:CGENCompugen Ltd
12/11/202413h00PR Newswire (US)Compugen Reports Third Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
11/11/202413h00PR Newswire (US)Compugen to Participate in Stifel 2024 Healthcare ConferenceNASDAQ:CGENCompugen Ltd
05/11/202415h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
05/11/202415h00PR Newswire (US)Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024NASDAQ:CGENCompugen Ltd
29/10/202412h00PR Newswire (US)Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024NASDAQ:CGENCompugen Ltd
07/10/202413h00PR Newswire (US)Compugen to Present New Clinical Data at SITC 2024NASDAQ:CGENCompugen Ltd
13/09/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
09/09/202413h00PR Newswire (US)Compugen to Present at Single Cell Genomics 2024 ConferenceNASDAQ:CGENCompugen Ltd
29/08/202413h00PR Newswire (US)Compugen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CGENCompugen Ltd
06/08/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
06/08/202413h00PR Newswire (US)Compugen Reports Second Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
05/08/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
29/07/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
29/07/202413h00PR Newswire (US)Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid TumorsNASDAQ:CGENCompugen Ltd
23/07/202413h00PR Newswire (US)Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024NASDAQ:CGENCompugen Ltd
17/06/202413h00PR Newswire (US)Compugen to Present at Upcoming Antibody Industrial SymposiumNASDAQ:CGENCompugen Ltd
30/05/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
30/05/202413h00PR Newswire (US)Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating RilvegostomigNASDAQ:CGENCompugen Ltd
20/05/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
20/05/202413h00PR Newswire (US)Compugen Reports First Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
20/05/202412h59IH Market NewsU.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices DipNASDAQ:CGENCompugen Ltd
16/05/202413h00PR Newswire (US)Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic PotentialNASDAQ:CGENCompugen Ltd
15/05/202413h02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
15/05/202413h00PR Newswire (US)Compugen Appoints David Silberman as Chief Financial OfficerNASDAQ:CGENCompugen Ltd
06/05/202413h00PR Newswire (US)Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024NASDAQ:CGENCompugen Ltd
25/04/202413h00PR Newswire (US)Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024NASDAQ:CGENCompugen Ltd
 Showing the most relevant articles for your search:NASDAQ:CGEN

Kürzlich von Ihnen besucht

BIT
NSCIT1312890
Republic of Romania
BIT
S31833
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten